Day One Biopharmaceuticals Inc’s recently made public that its HEAD OF R&D Blackman Samuel C. unloaded Company’s shares for reported $0.32 million on Jul 16 ’24. In the deal valued at $16.01 per share,20,000 shares were sold. As a result of this transaction, Blackman Samuel C. now holds 1,121,081 shares worth roughly $14.91 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Ramasastry Saira sold 10,000 shares, generating $131,877 in total proceeds. Upon selling the shares at $13.19, the Director now owns 40,485 shares.
Before that, Blackman Samuel C. sold 30,000 shares. Day One Biopharmaceuticals Inc shares valued at $378,588 were divested by the HEAD OF R&D at a price of $12.62 per share. As a result of the transaction, Blackman Samuel C. now holds 1,141,081 shares, worth roughly $15.18 million.
BofA Securities upgraded its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy from a an Underperform in a research note published on August 01, 2024; the price target was increased to $24 from $11. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in late April has reiterated a ‘”a Buy”‘ rating for it. BofA Securities also remained covering DAWN and has decreased its forecast on April 25, 2023 with a “an Underperform” recommendation from previously “Buy” rating. CapitalOne started covering the stock on February 08, 2023. It rated DAWN as “an Overweight”.
Price Performance Review of DAWN
On Friday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 1.29% to $13.30. Over the last five days, the stock has lost -4.45%. Day One Biopharmaceuticals Inc shares have fallen nearly -8.90% since the year began. Nevertheless, the stocks have risen 1.60% over the past one year. While a 52-week high of $18.07 was reached on 05/01/24, a 52-week low of $9.67 was recorded on 06/17/24. SMA at 50 days reached $13.96, while 200 days put it at $14.22. A total of 0.52 million shares were traded, compared to the trading of 0.68 million shares in the previous session.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 13.00, which if violated will result in even more drops to 12.71. On the upside, there is a resistance level at 13.55. A further resistance level may holdings at 13.81. The Relative Strength Index (RSI) on the 14-day chart is 40.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.36, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.75%. Stochastics%K at 12.32% indicates the stock is a buying.
The most recent change occurred on February 03, 2023 when Oppenheimer began covering the stock and recommended ‘”a Perform”‘ rating .
